NasdaqCM - Nasdaq Real Time Price USD

Inovio Pharmaceuticals, Inc. (INO)

10.57

+0.44

(+4.40%)

At close: 4:00 PM EDT

10.57

0.00

(0.00%)

After hours: 4:27 PM EDT

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477 shares of its common stock at an offering price of $7.692 per pre-funded warrant, in each case befor

PR Newswire 10 days ago

INO
+4.40%
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.

PR Newswire 30 days ago

INO
+4.40%
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?

The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks last month

INO
+4.40%
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2023 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2023 Earnings Call Transcript March 6, 2024 Inovio Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.12, expectations were $-1.58. Inovio Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and […]

Insider Monkey last month

INO
+4.40%
Q4 2023 Inovio Pharmaceuticals Inc Earnings Call

Q4 2023 Inovio Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents last month

INO
+4.40%
Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript

INO earnings call for the period ending December 31, 2023.

Motley Fool last month

INO
+4.40%
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the fourth quarter and full year ended December 31, 2023.

PR Newswire last month

INO
+4.40%
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting will be held in San Diego from April 5

PR Newswire last month

INO
+4.40%
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know

The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 2 months ago

INO
+4.40%
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that fourth quarter and year-end 2023 financial results will be released after the market close on March 6, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

PR Newswire 2 months ago

INO
+4.40%
Inovio (INO) Moves 17.4% Higher: Will This Strength Last?

Inovio (INO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

INO
+4.40%
JANX
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.

PR Newswire 2 months ago

INO
+4.40%
INOVIO Reports Inducement Grant Under Inducement Plan

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

PR Newswire 2 months ago

INO
+4.40%
How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%

The average of price targets set by Wall Street analysts indicates a potential upside of 223.7% in Inovio (INO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 2 months ago

INO
+4.40%
INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of 5:00 p.m. Eastern Time on Wednesday, January 24, 2024.

PR Newswire 3 months ago

INO
+4.40%
INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in a virtual fireside chat on the potential treatment of Recurrent Respiratory Papillomatosis (RRP). INOVIO's President and CEO, Dr. Jacqueline Shea, and Chief Medical Officer, Dr. Michael Sumner, will be joined by Dr. Simon Best, Otolaryngologist at Johns Hopki

PR Newswire 3 months ago

INO
+4.40%
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

Inovio Pharma (INO) surges 134% in a month, mainly due to its plans to submit a regulatory application seeking approval of its lead candidate, INO-3107, in the second half of 2024 to treat RRP.

Zacks 3 months ago

INO
+4.40%
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) to evaluate the combination of INO-3112 and LOQTORZI™ (toripalimab-tpzi) as a potential treatment for patients with locoregionally advanced, high-risk, HPV16/18 positive oropharyngeal squ

PR Newswire 3 months ago

INO
+4.40%
CHRS
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced plans to submit a BLA for INO-3107 as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) in the second half of 2024. This announcement follows an Initial Comprehensive Multidisciplinary Breakthrough Therapy (Type B) Meeting with the FDA on critical aspects of the data pa

PR Newswire 3 months ago

INO
+4.40%
The 3 Most Undervalued Biotech Stocks to Buy: November 2023

These companies in the biotechnology sector are doing incredible work and achieving wonderful developments. The result is not not only growth and profit for the companies, but they are also offering excellent and efficient solutions for the health of each one of us. Personally, the biotechnology sector is one of my favorite sectors because it is always growing and developing. If you are as interested in these companies as I am, here are 3 undervalued biotech stocks to take a look at. Inovio (INO

InvestorPlace 5 months ago

INO
+4.40%
ARCT

MDGL

Performance Overview

Return	INO	S&P 500
YTD	+72.71%	+6.92%
1-Year	+7.42%	+25.26%
3-Year	-87.14%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Inovio Pharmaceuticals, Inc. (INO)

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2023 Earnings Call Transcript

Q4 2023 Inovio Pharmaceuticals Inc Earnings Call

Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

Inovio (INO) Moves 17.4% Higher: Will This Strength Last?

INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

INOVIO Reports Inducement Grant Under Inducement Plan

How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%

INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program

The 3 Most Undervalued Biotech Stocks to Buy: November 2023

Performance Overview